Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy

Benton et al. identify binders against common mutant KRAS neoantigens and create peptide-centric CAR-T cells (NeoCARs). NeoCARs demonstrate a robust anti-tumor response against cancer cells expressing mutant KRAS peptides by MHC, both in vitro and in vivo. Inducible cytokine release and TCR deletion further enhance the therapeutic index.

Read the full article here

Related Articles